These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 31220959

  • 1. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
    Poveda JL, Trillo JL, Rubio-Terrés C, Rubio-Rodríguez D, Polanco A, Torres C.
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):295-303. PubMed ID: 31220959
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B, Guerreiro R, Costa J, Miguel LS.
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 4. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.
    Michels RE, de Fransesco M, Mahajan K, Hengstman GJD, Schiffers KMH, Budhia S, Harty G, Krol M.
    Appl Health Econ Health Policy; 2019 Dec; 17(6):857-873. PubMed ID: 31444659
    [Abstract] [Full Text] [Related]

  • 5. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
    Mankinen P, Lundström T, Soini E, Sumelahti ML, Ruutiainen J, Niskala U, Järvinen E.
    Adv Ther; 2020 Feb; 37(2):800-818. PubMed ID: 31873868
    [Abstract] [Full Text] [Related]

  • 6. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Lambe T, Duarte R, Mahon J, Nevitt S, Greenhalgh J, Boland A, Beale S, Kotas E, McEntee J, Pomeroy I.
    Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
    [Abstract] [Full Text] [Related]

  • 7. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E, Berger T, Bajer-Kornek B, Deisenhammer F.
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain.
    Ginestal R, Rubio-Terrés C, Morán OD, Rubio-Rodríguez D, Los Santos H, Ordoñez C, Sánchez-Magro I.
    J Comp Eff Res; 2023 Feb; 12(2):e220193. PubMed ID: 36705064
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T.
    J Med Econ; 2016 Feb; 19(4):432-42. PubMed ID: 26707273
    [Abstract] [Full Text] [Related]

  • 10. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ, Montgomery SM, Griffiths MJ, Bergvall N, Adlard N.
    J Med Econ; 2015 Feb; 18(11):874-85. PubMed ID: 26055952
    [Abstract] [Full Text] [Related]

  • 11. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Hua LH, Hersh CM, Morten P, Kusel J, Lin F, Cave J, Varga S, Herrera V, Ko JJ.
    J Manag Care Spec Pharm; 2019 Apr; 25(4):490-498. PubMed ID: 30917079
    [Abstract] [Full Text] [Related]

  • 12. Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon.
    Matni M, Yamout B, Koussa S, Khamis C, Fleifel L, Sharifi S, Mohamed O.
    Mult Scler Relat Disord; 2022 Nov; 67():104169. PubMed ID: 36150262
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia.
    Lasalvia P, Hernández F, Castañeda-Cardona C, Cuestas JA, Rosselli D.
    Value Health Reg Issues; 2020 Dec; 23():13-18. PubMed ID: 31999987
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
    Brownlee WJ, Haghikia A, Hayward B, Waser N, Kayaniyil S, Khan Z, Duncan J, Millar S, Harty GT.
    Mult Scler Relat Disord; 2023 Aug; 76():104791. PubMed ID: 37343465
    [Abstract] [Full Text] [Related]

  • 17. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States.
    Chirikov V, Ma I, Joshi N, Patel D, Smith A, Giambrone C, Cornelio N, Hashemi L.
    Value Health; 2019 Feb; 22(2):168-176. PubMed ID: 30711061
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.
    J Med Econ; 2012 Feb; 15(6):1088-96. PubMed ID: 22583065
    [Abstract] [Full Text] [Related]

  • 20. Economic Evaluation of Cladribine Tablets in Patients With High Disease Activity-Relapsing-Remitting Multiple Sclerosis in the Kingdom of Saudi Arabia.
    Bohlega S, Elboghdady A, Al-Johani A, Mahajan K, Mughari MK, Al-Saqa'aby M, Mohamed O, Alarieh R, Al Malik Y.
    Value Health Reg Issues; 2021 Sep; 25():189-195. PubMed ID: 34425468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.